Correlation between Serum Oncogene Protein Expression and the Development of Neoplastic Disease in a Worker Exposed to Carcinogens

Expression of p21ras-related protein in the plasma and tissue of patients with adenomas and carcinomas of the colon

Abstract Over-expression of p21 ras-related protein was determined in the plasma by immunoblotting and in the tissue by immuno-histochemistry in a cohort of patients undergoing colonoscopy. In the plasma samples, p21 ras over-expression was detected in: 9% (4/47) of normal controls; 21% (13/61) of individuals with normal colonoscopies but with a prior history of colonic neoplasia; 12% (4/33) of small adenoma patients, 29% (6/21) of large adenoma patients; 63% (5/8) of carcinoma-in-adenoma patients; 50% (2/4) of Dukes' A carcinoma patients; and 20% (2/10) of Dukes' B-D carcinoma patients. In the tissue samples, p21 ras over-expression was detected in: 25% (2/8) of small adenoma patients; 44% (4/9) of large adenoma patients; 100% (4/4) of carcinoma-in-adenoma patients; and 33% (1/3) of Dukes' B-C carcinoma patients. For matched plasma-tissue pairs, there was a statistically significant correlation for p21 ras over-expression (R = 0.47, p = 0.02).

Examination of ras oncoproteins in human plasma from healthy controls and workers exposed to petroleum emissions, including benzene-related compounds

Ras oncoproteins in blood plasma from workers exposed to petroleum emissions and unexposed controls were examined from Polish and Estonian samples. Twenty-four workers and 35 unexposed controls were examined from Poland and 97 exposed and 40 unexposed controls from Estonia. Of the Estonian workers, 50 were exposed to benzene in a benzene production plant and 47 to polyaromatic hydrocarbons and benzene in a cokery. Blood plasma proteins were separated by gel electrophoresis, transferred to a nitrocellulose membrane by Western blotting and detected by chemiluminescence using a monoclonal antibody as the primary antibody. There were no statistically significant differences between the exposed and the control groups in either the Polish or the Estonian samples.

Molecular markers of carcinogenesis

The protein products of oncogenes and tumor suppressor genes play critical roles in the development of many cancers. The expression of a number of these proteins can be detected in extracellular fluids such as blood. This article reviews the literature on the application of methods for the detection of the proteins of oncogenes and tumor suppressor genes in the blood of humans with cancer or at risk for the development of cancer. The detection of these proteins in blood may be useful molecular markers of carcinogenesis that could play an important part in cancer diagnosis, prognosis, and prevention.

Examination of ras (P21) proteins in plasma from workers exposed to benzene emissions from petrochemical plants and healthy controls

Exposure of workers to benzene and polyaromatic hydrocarbons has been documented to be at relatively high levels in the production of benzene and in the coking process at a petrochemical plant in the oil shale area in Estonia. Altogether 97 plasma samples from workers and 40 from unexposed matched referents from two samplings in different seasons were analyzed for the presence of ras (P21) proteins; of the workers 50 were exposed to benzene in the benzene production plant and 47 to polyaromatic hydrocarbons and benzene in a cokery. Proteins were separated by gel electrophoresis, transferred to a nitrocellulose membrane by Western blotting and detected by chemiluminescence, using a monoclonal antibody as the primary antibody. There were no statistically significant differences between the exposed and the referent groups. The results are thus in keeping with the lack of exposure related cytogenetic effects for this same workforce.

Molecular epidemiology: cancer risk assessment using biomarkers for detecting early health effects in individuals exposed to occupational and environmental carcinogens

Detecting changes that precede the overt symptoms of cancer and identifying measurable indices of such changes in persons exposed to occupational and environmental carcinogens constitutes one of the primary objectives of molecular epidemiology research. Biomarkers represent a valuable research tool that makes it possible to attain that objective. Suitably selected biomarker sets may provide information on the extent of exposure to carcinogenic agents (internal dose, biologically effective dose), detect early changes caused by those agents in the exposed organism, and identify individuals with a particularly high risk of cancer development. The tremendous progress in research on the mechanisms of cancer initiation and promotion has enabled the assessment of cancer risk in healthy individuals by examining specific results from determinations of suitably selected biomarkers. The finding that gene defects (gene mutations and changes of their expression) constitute the background of carcinogenesis has resulted in molecular biology becoming focused on detecting defective genes or proteins synthesized under control of the defective genes.

Biomarkers of gene expression: growth factors and oncoproteins

This article reviews the literature on the application of methods for the detection of growth factors, oncogene proteins, and tumor-suppressor gene proteins in the blood of humans with cancer or who are at risk for the development of cancer. The research summarized here suggests that many of these biomarker assays can be used to distinguish between diseased and nondiseased states and in some instances may be able to predict susceptibility for future disease. Thus, these biomarkers could be valuable tools for monitoring at-risk populations for purposes of disease prevention and control.

Laboratory probing of oncogenes from human liquid and solid specimens as markers of exposure to toxicants

Recent discoveries regarding the mechanistic role of oncogenes and tumor suppressor genes in cancer development have opened a new era of molecular diagnosis. It has been observed repeatedly that genetic lesions serve as tumor markers in a broad variety of human cancers. The ras gene family, consisting of three related genes, H-ras, K-ras, and N-ras, acquires transforming activity through amplification or mutation in many tissues. If not all, then most types of human malignancies have been found to contain an altered ras gene. Because the ras oncogenes actively participate in both early and intermediate stages of cancer, several highly specific and sensitive approaches have been introduced to detect these genetic alterations as biomarkers of exposure to carcinogens. There is also mounting evidence that implicate chemical-specific alterations of the p53 tumor suppressor gene detected in most human tumors. Therefore, it seems a reliable laboratory approach to identify both altered p53 and ras genes as biomarkers of human chronic or intermittent exposure to toxicants in a variety of occupational settings.

Levels of ras oncoproteins in human plasma from 1,3-butadiene-exposed workers and controls

In a Czech plant near Prague, 10 samples from male workers occupationally exposed to 1,3-butadiene and 13 exposed to 1,3-butadiene/styrene were compared with unexposed male negative controls, matched for age and smoking habits, for the presence of ras oncoproteins in their plasma. Proteins were separated by gel electrophoresis, transferred to a nitrocellulose membrane by Western blotting and detected by chemiluminescence, using monoclonal ras antibody as the primary antibody. There were no statistically significant differences between the 3 groups (pooled two-sample t-test, untransformed and non-parametric Mann-Whitney test). These results are in keeping with the lack of exposure-related effects for 3 cytogenetic endpoints (chromosome aberrations, sister chromatid exchanges and micronuclei) already reported (Sorsa et al., 1994 Mutation Res., 309, 321-326) for this work-force exposed to low (below 3 ppm) exposure levels.

Oncogene proteins as biomarkers in the molecular epidemiology of occupational carcinogenesis. The example of the ras oncogene-encoded p21 protein

The use of oncogene proteins as biomarkers offers a new approach to the molecular epidemiologic evaluation of occupational carcinogenesis. The ras oncogene-encoded p21 protein represents a prototype for this type of study, since it is known to be activated by common occupational carcinogens, is frequently found in human tumors of occupational concern, and, at least in certain instances, appears to be expressed relatively early in the disease process, allowing the possibility of early detection and intervention. Herein, we review our experience with the use of immunologic detection of p21 in cohorts with cancer or at risk for the development of cancer due to their occupational exposures. The results suggest that p21 (particularly when used with other oncoproteins and biomarkers such as PAH-DNA adducts) will indeed be a useful addition to the growing armamentarium of molecular epidemiologic biomarkers in the study of occupational carcinogenic mechanisms and in the detection and prevention of occupational cancers.